Intensive Blood Glucose Control and Vascular Outcomes in …
2008年6月12日 · The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial was designed to assess the effects on major …
A Summary of the ADVANCE Trial - Diabetes Care
2009年11月1日 · The ADVANCE study has answered a number of important questions regarding glycemic control in patients with type 2 diabetes. It has clearly demonstrated that it is possible …
The ADVANCE Trial : results, clinical implications and perspectives
2008年3月18日 · The ADVANCE Trial is the largest-ever study aimed at investigating the effects of a treatment based on the fixed combination of an ACE-inhibitor (perindopril, 2mg) and a …
What did the ACCORD, ADVANCE, and VA Diabetes trials show?—
2009年1月1日 · The ADVANCE study randomized 11,140 participants at sites in Europe, Australia/New Zealand, Canada, and Asia to a strategy of intensive glycemic control (with …
Follow-up of Blood-Pressure Lowering and Glucose Control in …
2014年10月9日 · In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of …
The ADVANCE trial - The Lancet
2008年1月5日 · Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The ADVANCE study1 …
The ADVANCE trial - new findings and updated results
2011年4月30日 · New data regard the blood pressure and the glucose lowering arms, atrial fibrillation and renal outcome. Authors further report on the benefit of the …
We randomly assigned 11,140 patients with type 2 diabetes to undergo either stan-dard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus …
Rationale and design of the ADVANCE study: a randomised trial …
Objectives: To determine the effects on macrovascular and microvascular disease of first, lowering blood pressure using a very-low-dose angiotensin-converting enzyme (ACE) inhibitor …
[ADVANCE study: objectives, design and current status]
Objectives: ADVANCE (Action in Diabetes and Vascular disease; preterAx and diamicroN-MR Controlled Evaluation) will examine the hypotheses that intensive blood pressure lowering …